Colony Group’s Forte Biosciences FBRX Stock Holding History

Colony Group’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-99	Closed	-$45K	–	694
2020 Q1	$45K	Hold	99	–	–	﹤0.01%	660
2019 Q4	$20K	Hold	99	–	–	﹤0.01%	735
2019 Q3	$25K	Hold	99	–	–	﹤0.01%	691
2019 Q2	$248K	Hold	99	–	–	0.01%	655
2019 Q1	$404K	Hold	99	–	–	0.02%	446
2018 Q4	$305K	Hold	99	–	–	0.01%	403
2018 Q3	$579K	Hold	99	–	–	0.03%	323
2018 Q2	$347K	Hold	99	–	–	0.02%	388
2018 Q1	$440K	Hold	99	–	–	0.02%	350
2017 Q4	$381K	Buy	+99	New	+$395K	0.02%	355

Other funds holding FBRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Colony Group's FBRX Position: Q2 2020 in Review

Colony Group sold out of Forte Biosciences (FBRX) in Q2 2020, closing a stake of 99 shares — an estimated $45K sold.

Colony Group first reported a position in FBRX in Q4 2017 and held it in 10 quarters. The position peaked at $579K in Q3 2018. 27 funds tracked by Wall St. Rank hold FBRX as of Q2 2020.

Colony Group reported no remaining Forte Biosciences position as of Q2 2020 after selling out during the quarter.
Colony Group sold 99 Forte Biosciences shares in Q2 2020, an estimated $45K.
Colony Group first reported a position in Forte Biosciences in Q4 2017 and held it in 10 quarters.
Colony Group's Forte Biosciences position peaked at $579K in Q3 2018.
27 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2020.

Based on Colony Group's 13F filing for Q2 2020, filed 13 Aug 2020.